Drug intelligence / Profile preview

C1 inhibitor, human

Development stage
Approved
Lead developer
CSL Behring
Modality
Recombinant Proteins and Enzymes
Administration
Intravenous, Subcutaneous
01

Overview

C1 inhibitor, human is a purified plasma-derived protein that functions as a serine protease inhibitor (serpin) and is used to treat and prevent hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body. The drug works by replacing deficient or dysfunctional endogenous C1-inhibitor in patients with HAE. Mechanistically, it inhibits several key proteins in the complement and contact system pathways—including C1s, kallikrein, factor XIIa, and XIa—thereby preventing excessive bradykinin production and subsequent increases in vascular permeability that lead to angioedema attacks. It is administered intravenously or subcutaneously depending on the product formulation. Brand names include Berinert (for acute attacks), Cinryze (for prophylaxis), and Haegarda (for prophylaxis). The primary indication is hereditary angioedema[3][5][6][8].

Brand names
BerinertCinryzeHaegarda
Other names
c1 inhibitor, humanc1 esterase inhibitor, humancomplement component 1 esterase inhibitor, human
02

Targets

FXIIa (Coagulation Factor XIIa)Factor XIaC1R (Complement component 1r subcomponent)C1S (Complement component 1s subcomponent serine protease)MASP1 (MASP-1)MASP2 (Mannan-binding lectin-associated serine protease 2)KLKB1 (Plasma kallikrein)COL4 (Collagen IV)

Beyond the preview

Go deeper on C1 inhibitor, human.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on C1 inhibitor, human.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call